Section Arrow
Quote
DFTX.NASDAQ
- Definium Therapeutics Inc
Quotes are at least 15-min delayed:2026/04/22 04:37 EDT
Pre Market
Last
 24.3
+0.46 (+1.93%)
Bid
24.1
Ask
24.4
High 24.36 
Low 23.85 
Volume 1.14K 
Regular Hours (Closed)
Last
 23.84
+0.66 (+2.85%)
Day High 
24.17 
Prev. Close
23.18 
1-M High
26.25 
Volume 
2.63M 
Bid
24.1
Ask
24.4
Day Low
22.8301 
Open
23.75 
1-M Low
17.13 
Market Cap 
2.31B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 21.92 
20-SMA 20.42 
50-SMA 18.72 
52-W High 26.25 
52-W Low 6.03 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.06/-2.67
Enterprise Value
2.35B
Balance Sheet
Book Value Per Share
3.33
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
Pre Market 0.2128 +0.016 +8.13%
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
Pre Market 2.4032 -0.2868 -10.66%
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
Pre Market 0.3257 -0.013 -3.84%
GERNGeron Corp1.5-0.06-3.85%-- 
Pre Market 1.52 +0.02 +1.33%
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Pre Market 5.5305 -0.4595 -7.67%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial andoperational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.